{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T13:14:39Z","timestamp":1778591679530,"version":"3.51.4"},"reference-count":40,"publisher":"Pleiades Publishing Ltd","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dokl Biochem Biophys"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1134\/s1607672925700231","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:15:14Z","timestamp":1774898114000},"page":"81-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial"],"prefix":"10.1134","volume":"526","author":[{"given":"T. A.","family":"Lisitsyna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Abramkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. Yu.","family":"Veltishchev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. B.","family":"Borisova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. L.","family":"Nasonov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"key":"7794_CR1","volume-title":"Classification and epidemiology of rheumatoid arthritis, Rheumatology","author":"K.P. Liao","year":"2015","unstructured":"Liao, K.P. and Karlson, E.W., Classification and epidemiology of rheumatoid arthritis, Rheumatology, Hochberg, M.C., Silman, A.J., Smolen, J.S., Weinblatt, M.E., and Weisman, M.H., Eds., Maryland Heights, MO, USA: Elsevier Mosby, 2015, pp. 691\u2013697."},{"key":"7794_CR2","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1016\/s0140-6736(16)30173-8","volume":"388","author":"J.S. Smolen","year":"2016","unstructured":"Smolen, J.S., Aletaha, D., and Mcinnes, I.B., Rheumatoid arthritis, Lancet, 2016, vol. 388, no. 10055, pp.\u00a02023\u20132038. https:\/\/doi.org\/10.1016\/s0140-6736(16)30173-8","journal-title":"Lancet"},{"key":"7794_CR3","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s40744-020-00217-4","volume":"7","author":"M.N. Lwin","year":"2020","unstructured":"Lwin, M.N., Serhal, L., Holroyd, Ch., and Edwards,\u00a0Ch.J., Rheumatoid arthritis: the impact of mental health on disease: a narrative review, Rheumatol. Ther., 2020, vol. 7, no. 3, pp. 457\u2013471. https:\/\/doi.org\/10.1007\/s40744-020-00217-4","journal-title":"Rheumatol. Ther."},{"key":"7794_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jocn.2019.08.027","volume":"69","author":"B.K. Vitturi","year":"2019","unstructured":"Vitturi, B.K., Nascimento, B.A.C., Alves, B.R., De\u00a0Campos, F.S.C., and Torigoe, D.Yu., Cognitive impairment in patients with rheumatoid arthritis, J.\u00a0Clin. Neurosci., 2019, vol. 69, pp. 81\u201387. https:\/\/doi.org\/10.1016\/j.jocn.2019.08.027","journal-title":"J.\u00a0Clin. Neurosci."},{"key":"7794_CR5","doi-asserted-by":"publisher","first-page":"22","DOI":"10.26442\/00403660.2020.05.000624","volume":"92","author":"A.A. Abramkin","year":"2020","unstructured":"Abramkin, A.A., Lisitsyna, T.A., Veltishchev, D.Yu., Seravina, O.F., Kovalevskaya, O.B., Glukhova, S.I., and Nasonov, E.L., Depression and severity of articular destruction in patients with rheumatoid arthritis, Ter. Arkh., 2020, vol. 92, no. 5, pp. 22\u201332. https:\/\/doi.org\/10.26442\/00403660.2020.05.000624","journal-title":"Ter. Arkh."},{"key":"7794_CR6","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.2147\/prbm.s482409","volume":"17","author":"L.R. Baghdadi","year":"2024","unstructured":"Baghdadi, L.R., Tocilizumab reduces depression risk in rheumatoid arthritis patients: a systematic review and meta-analysis, Psychol. Res. Behav. Manage., 2024, vol.\u00a017, pp. 3419\u20133441. https:\/\/doi.org\/10.2147\/prbm.s482409","journal-title":"Psychol. Res. Behav. Manage."},{"key":"7794_CR7","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.3390\/medicina58111637","volume":"58","author":"C.-E. Ionescu","year":"2022","unstructured":"Ionescu, C.-E., Popescu, C.C., Agache, M., Dinache, G., and Codreanu, C., Depression in rheumatoid arthritis: a narrative review\u2014diagnostic challenges, pathogenic mechanisms and effects, Medicina, 2022, vol. 58, no. 11, p. 1637. https:\/\/doi.org\/10.3390\/medicina58111637","journal-title":"Medicina"},{"key":"7794_CR8","doi-asserted-by":"publisher","unstructured":"Sch\u00e4fer, M., Albrecht, K., Kekow, J., Rockwitz, K., Liebhaber, A., and Zink, A., Factors associated with treatment satisfaction in patients with rheumatoid arthritis: data from the biological register RABBIT, RMD Open, 2020, vol. 6, p. e001290. https:\/\/doi.org\/10.1136\/rmdopen-2020001290","DOI":"10.1136\/rmdopen-2020001290"},{"key":"7794_CR9","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/mp.2016.3","volume":"21","author":"D.R. Goldsmith","year":"2016","unstructured":"Goldsmith, D.R., Rapaport, M.H., and Miller, B.J., A\u00a0meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression, Mol. Psychiatry, 2016, vol. 21, no. 12, pp. 1696\u20131709. https:\/\/doi.org\/10.1038\/mp.2016.3","journal-title":"Mol. Psychiatry"},{"key":"7794_CR10","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1017\/s0033291717000745","volume":"47","author":"G.M. Khandaker","year":"2017","unstructured":"Khandaker, G.M., Dantzer, R., and Jones, P.B., Immunopsychiatry: important facts, Psychological Med., 2017, vol. 47, no. 13, pp. 2229\u20132237. https:\/\/doi.org\/10.1017\/s0033291717000745","journal-title":"Psychological Med."},{"key":"7794_CR11","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.3390\/ijms21062194","volume":"21","author":"E.Y.-C. Ting","year":"2020","unstructured":"Ting, E.Y.-C., Yang, A.C., and Tsai, S.-J., Role of interleukin-6 in depressive disorder, Int. J. Mol. Sci., 2020, vol. 21, no. 6, p. 2194. https:\/\/doi.org\/10.3390\/ijms21062194","journal-title":"Int. J. Mol. Sci."},{"key":"7794_CR12","doi-asserted-by":"publisher","first-page":"318","DOI":"10.14412\/1995-4484-2019-318-327","volume":"57","author":"T.A. Lisitsyna","year":"2019","unstructured":"Lisitsyna, T.A., Veltishchev, D.Yu., Lila, A.M., and Nasonov, E.L., Interleukin 6 as a pathogenic factor mediating clinical manifestations and a therapeutic target for rheumatic diseases and depressive disorders, Rheumatol. Sci. Pract., 2019, vol. 57, no. 3, pp. 318\u2013327. https:\/\/doi.org\/10.14412\/1995-4484-2019-318-327","journal-title":"Rheumatol. Sci. Pract."},{"key":"7794_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41573-021-00368-1","volume":"21","author":"W.C. Drevets","year":"2022","unstructured":"Drevets, W.C., Wittenberg, G.M., Bullmore, E.T., and Manji, H.K., Immune targets for therapeutic development in depression: towards precision medicine, Nat. Rev. Drug Discovery, 2022, vol. 21, no. 3, pp. 224\u2013244. https:\/\/doi.org\/10.1038\/s41573-021-00368-1","journal-title":"Nat. Rev. Drug Discovery"},{"key":"7794_CR14","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s40744-023-00612-7","volume":"11","author":"G. Citera","year":"2024","unstructured":"Citera, G., Jain, R., Irazoque, F., Madariaga, H., Gruben, D., Wang, L., Stockert, L., Santana, K., Ebrahim, A., and Ponce De Leon, D., Tofacitinib efficacy in patients with rheumatoid arthritis and probable depression\/anxiety: post hoc analysis of phase 3 and 3b\/4 randomized controlled trials, Rheumatol. Ther., 2024, vol.\u00a011, no. 1, pp. 35\u201350. https:\/\/doi.org\/10.1007\/s40744-023-00612-7","journal-title":"Rheumatol. Ther."},{"key":"7794_CR15","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1136\/annrheumdis-2021-219876","volume":"81","author":"E. Nasonov","year":"2022","unstructured":"Nasonov, E., Fatenejad, S., Feist, E., Ivanova, M., Korneva, E., Krechikova, D.G., Maslyanskiy, A.L., Samsonov, M., Stoilov, R., Zonova, E.V., and Genovese, M., Olokizumab, a monoclonal antibody against interleukin 6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by methotrexate: efficacy and safety results of a randomised controlled phase III study, Ann. Rheum. Dis., 2022, vol. 81, no. 4, pp. 469\u2013479. https:\/\/doi.org\/10.1136\/annrheumdis-2021-219876","journal-title":"Ann. Rheum. Dis."},{"key":"7794_CR16","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1136\/ard-2022-222630","volume":"81","author":"E. Feist","year":"2022","unstructured":"Feist, E., Fatenejad, S., Grishin, S., Korneva, E., Luggen, M.E., Nasonov, E., Samsonov, M., Smolen, J.S., and Fleischmann, R.M., Olokizumab, a monoclonal antibody against interleukin-6, in combination with methotrexate in patients with rheumatoid arthritis inadequately controlled by tumour necrosis factor inhibitor therapy: efficacy and safety results of a randomised controlled phase III study, Ann. Rheum. Dis., 2022, vol.\u00a081, no. 12, pp. 1661\u20131668. https:\/\/doi.org\/10.1136\/ard-2022-222630","journal-title":"Ann. Rheum. Dis."},{"key":"7794_CR17","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1056\/nejmoa2201302","volume":"387","author":"J.S. Smolen","year":"2022","unstructured":"Smolen, J.S., Feist, E., Fatenejad, S., Grishin, S.A., Korneva, E.V., Nasonov, E.L., Samsonov, M.Y., and Fleischmann, R.M., Olokizumab versus placebo or adalimumab in rheumatoid arthritis, N. Engl. J. Med., 2022, vol. 387, no. 8, pp. 715\u2013726. https:\/\/doi.org\/10.1056\/nejmoa2201302","journal-title":"N. Engl. J. Med."},{"key":"7794_CR18","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1136\/ard-2023-225473","volume":"83","author":"E. Feist","year":"2024","unstructured":"Feist, E., Fleischmann, R.M., Fatenejad, S., Bukhanova, D., Grishin, S., Kuzkina, S., Luggen, M., Nasonov, E., Samsonov, M., and Smolen, J.S., Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment, Ann. Rheum. Dis., 2024, vol. 83, no.\u00a011, pp. 1454\u20131464. https:\/\/doi.org\/10.1136\/ard-2023-225473","journal-title":"Ann. Rheum. Dis."},{"key":"7794_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.47360\/1995-4484-2023-188-198","volume":"61","author":"T.A. Lisitsyna","year":"2023","unstructured":"Lisitsyna, T.A., Abramkin, A.A., Veltishchev, D.Yu., Seravina, O.F., Kovalevskaya, O.B., Borisova, A.B., Ignatiev, V.G., and Nasonov, E.L., Efficacy of olokizumab against comorbid depressive disorder in patients with rheumatoid arthritis: Preliminary results of the study, Nauchno-Prakt. Revmatol., 2023, vol. 61, no. 2, pp.\u00a0188\u2013198. https:\/\/doi.org\/10.47360\/1995-4484-2023-188-198","journal-title":"Nauchno-Prakt. Revmatol."},{"key":"7794_CR20","doi-asserted-by":"publisher","first-page":"s14","DOI":"10.1002\/acr.20621","volume":"63","author":"J.K. Anderson","year":"2011","unstructured":"Anderson, J.K., Zimmerman, L., Caplan, L., and Michaud, K., Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28-Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score-II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis Disease Activity Index-5 (RADAI-5), Chronic Arthritis Systemic Index (CASI), Patient-Based Disease Activity Score With ESR (PDAS1) and Patient-Based Disease Activity Score Without ESR (PDAS2), and Mean Overall Index for Rheumatoid Arthritis (MOI-RA), Arthritis Care Res. (Hoboken), 2011, vol. 63, no. s11, pp. s14\u2013s36. https:\/\/doi.org\/10.1002\/acr.20621","journal-title":"Arthritis Care Res."},{"key":"7794_CR21","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.1001\/jama.2020.6504","volume":"323","author":"B. Levis","year":"2020","unstructured":"Levis, B., Sun, Yi., He, Ch., Wu, Yi., Krishnan, A., Bhandari, P.M., Neupane, D., Imran, M., Brehaut, E., Negeri, Z., Fischer, F.H., Benedetti, A., and Thombs, B.D., Accuracy of the PHQ-2 alone and in combination with the PHQ-9 for screening to detect major depression, JAMA, 2020, vol. 323, no. 22, pp.\u00a02290\u20132300. https:\/\/doi.org\/10.1001\/jama.2020.6504","journal-title":"JAMA"},{"key":"7794_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1192\/bjp.134.4.382","volume":"134","author":"S.A. Montgomery","year":"1979","unstructured":"Montgomery, S.A. and \u00c5sberg, M., A new depression scale designed to be sensitive to change, Br. J. Psychiatry, 1979, vol. 134, no. 4, pp. 382\u2013389. https:\/\/doi.org\/10.1192\/bjp.134.4.382","journal-title":"Br. J. Psychiatry"},{"key":"7794_CR23","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M. Hamilton","year":"1959","unstructured":"Hamilton, M., The assessment of anxiety states by rating, Br. J. Med. Psychol., 1959, vol. 32, no. 1, pp. 50\u201355. https:\/\/doi.org\/10.1111\/j.2044-8341.1959.tb00467.x","journal-title":"Br. J. Med. Psychol."},{"key":"7794_CR24","volume-title":"The Study of Signs of Depressive States by the \u201cPictogram\u201d","author":"L.S. Dragoonskaya","year":"1976","unstructured":"Dragoonskaya, L.S., The Study of Signs of Depressive States by the \u201cPictogram\u201d \n               Method. Experimental Studies in Pathopsychology, Moscow, 1976."},{"key":"7794_CR25","unstructured":"Loginova, S.V. and Rubinstein, S.A., On the Application of the \u201cPictograms\u201d Method for the Experimental Study of Mental Patients\u2019 Thinking, Moscow, 1972."},{"key":"7794_CR26","unstructured":"Zeigarnik, B.V., Thinking Disorders in Mentally Ill (Experimental Psychological Study), Moscow, 1958."},{"key":"7794_CR27","volume-title":"Pathology of Thinking","author":"B.V. Zeigarnik","year":"1962","unstructured":"Zeigarnik, B.V., Pathology of Thinking, Moscow: Publishing House of Moscow State University, 1962."},{"key":"7794_CR28","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/1477-7525-1-20","volume":"9","author":"B. Bruce","year":"2003","unstructured":"Bruce, B. and Fries, J.F., The Stanford Health Assessment Questionnaire: dimensions and practical applications, Health Qual. Life Outcomes, 2003, vol. 9, p. 20.","journal-title":"Health Qual. Life Outcomes"},{"key":"7794_CR29","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","volume":"20","author":"M. Herdman","year":"2011","unstructured":"Herdman, M., Gudex, C., Lloyd, A., Janssen, Mf., Kind, P., Parkin, D., Bonsel, G., and Badia, X., Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L), Qual. Life Res., 2011, vol. 20, no. 10, pp. 1727\u20131736. https:\/\/doi.org\/10.1007\/s11136-011-9903-x","journal-title":"Qual. Life Res."},{"key":"7794_CR30","volume-title":"ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines","author":"World Health Organization","year":"1993","unstructured":"World Health Organization, ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines, Geneva: World Health Organization, 1993."},{"key":"7794_CR31","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Arlington: American Psychiatric Association, 2013, 5th ed."},{"key":"7794_CR32","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.autrev.2012.11.010","volume":"12","author":"O.M. Epis","year":"2013","unstructured":"Epis, O.M., Giacomelli, L., Deidda, S., and Bruschi, E., Tight control applied to the biological therapy of rheumatoid arthritis, Autoimmun. Rev., 2013, vol. 12, no. 8, pp. 839\u2013841. https:\/\/doi.org\/10.1016\/j.autrev.2012.11.010","journal-title":"Autoimmun. Rev."},{"key":"7794_CR33","doi-asserted-by":"publisher","unstructured":"Taylor, P.C., Feist, E., Pope, J.E., Nash, P., Sibilia, J., Caporali, R., and Balsa, A., What have we learnt from the inhibition of IL-6 in RA and what are the clinical opportunities for patient outcomes?, Ther. Adv. Musculoskeletal Dis., 2024, vol. 21, no. 16, p. 1759720x241283340. https:\/\/doi.org\/10.1177\/1759720x241283340","DOI":"10.1177\/1759720x241283340"},{"key":"7794_CR34","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1038\/s41380-019-0471-8","volume":"25","author":"G.M. Wittenberg","year":"2020","unstructured":"Wittenberg, G.M., Stylianou, A., Zhang, Yu., Sun, Yu., Gupta, A., Jagannatha, P.S., Wang, D., Hsu, B., Curran, M.E., Khan, Sh., Chen, G., Bullmore, E.T., and Drevets, W.C., Effects of immunomodulatory drugs on depressive symptoms: A mega-analysis of randomized, placebo-controlled clinical trials in inflammatory disorders, Mol. Psychiatry, 2020, vol. 25, no. 6, pp. 1275\u20131285. https:\/\/doi.org\/10.1038\/s41380-019-0471-8","journal-title":"Mol. Psychiatry"},{"key":"7794_CR35","doi-asserted-by":"publisher","first-page":"680","DOI":"10.14412\/1995-4484-2013-680-5","volume":"51","author":"A.S. Starkova","year":"2013","unstructured":"Starkova, A.S., Amirdzhanova, V.N., Panasyuk, E.Yu., and Nasonov, E.L., Functional ability and quality of life in patients with rheumatoid arthritis receiving tocilizumab therapy, Rheumatol. Sci. Pract., 2013, vol. 51, no. 6, p. 680. https:\/\/doi.org\/10.14412\/1995-4484-2013-680-5","journal-title":"Rheumatol. Sci. Pract."},{"key":"7794_CR36","doi-asserted-by":"publisher","unstructured":"Gerasimova, E.V., Popkova, T.V., Gerasimova, D.A., and Kondratyuk, P.A., Quality of life and functional assessment insufficiency, anxiety and depression screening in patients with rheumatoid arthritis on the background during five years of tocilizumab therapy, Curr. Probl. Health Care Med. Stat., 2023, vol. 4, pp. 47\u201362. https:\/\/doi.org\/10.24412\/2312-2935-2023-4-47-62","DOI":"10.24412\/2312-2935-2023-4-47-62"},{"key":"7794_CR37","doi-asserted-by":"publisher","first-page":"551","DOI":"10.55563\/clinexprheumatol\/yu55rd","volume":"40","author":"F. Behrens","year":"2022","unstructured":"Behrens, F., Burmester, G.-R., Feuchtenberger, M., Kellner, H., Kuehne, C., Liebhaber, A., Wassenberg, S., Gerlach, J., Zortel, M., Hofmann, M.W., and Amberger, Ch., Characterisation of depressive symptoms in rheumatoid arthritis patients treated with tocilizumab during routine daily care, Clin. Exp. Rheumatol., 2022, vol. 40, no. 3, pp. 551\u2013559. https:\/\/doi.org\/10.55563\/clinexprheumatol\/yu55rd","journal-title":"Clin. Exp. Rheumatol."},{"key":"7794_CR38","doi-asserted-by":"publisher","unstructured":"Tiosano, Sh., Yavne, Ya., Watad, A., Langevitz, P., Lidar, M., Feld, J., Tishler, M., Aamar, S., Elkayam, O., Balbir-gurman, A., Molad, Ya., Ehrlich, Sh., Abushakra, M., Amital, D., and Amital, H., The impact of tocilizumab on anxiety and depression in patients with rheumatoid arthritis, Eur. J. Clin. Invest., 2020, vol. 50, no. 9, p. e13268. https:\/\/doi.org\/10.1111\/eci.13268","DOI":"10.1111\/eci.13268"},{"key":"7794_CR39","first-page":"292","volume":"43","author":"G. Salvadore","year":"2018","unstructured":"Salvadore, G., Nash, A., and Bleys, C., A double-blind, placebo-controlled, multicenter study of sirukumab as adjunctive treatment to a monoaminergic antidepressant in adults with major depressive disorder, Neuropsychopharmacology, 2018, vol. 43, p. 292.","journal-title":"Neuropsychopharmacology"},{"key":"7794_CR40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/npp.2017.258","volume":"43","author":"R.R. Girgis","year":"2018","unstructured":"Girgis, R.R., Ciarleglio, A., Choo, T., Haynes, G., Bathon, J.M., Cremers, S., Kantrowitz, J.T., Lieberman,\u00a0J.A., and Brown, A.S., A randomized, double-blind, placebo-controlled clinical trial of tocilizumab, an interleukin-6 receptor antibody, for residual symptoms in schizophrenia, Neuropsychopharmacology, 2018, vol. 43, no. 6, pp. 1317\u20131323. https:\/\/doi.org\/10.1038\/npp.2017.258","journal-title":"Neuropsychopharmacology"}],"container-title":["Doklady Biochemistry and Biophysics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672925700231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S1607672925700231","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S1607672925700231.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:49:28Z","timestamp":1778590168000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S1607672925700231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7794"],"URL":"https:\/\/doi.org\/10.1134\/s1607672925700231","relation":{},"ISSN":["1607-6729","1608-3091"],"issn-type":[{"value":"1607-6729","type":"print"},{"value":"1608-3091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"20 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Academic Council (Protocol no. 20 dated December 22, 2020) and the local ethics committee (protocol no. 19 dated October 28, 2021) of the Nasonova Research Institute of Rheumatology (NRIR). All participants signed a voluntary informed consent to participate in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"ETHICS APPROVAL AND CONSENT TO PARTICIPATE"}},{"value":"The authors of this work declare that they have no conflicts of interest. The authors bear full responsibility for submitting the final version of the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"CONFLICT OF INTEREST"}}]}}